Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Retained Earnings (2017 - 2025)

Autolus Therapeutics' Retained Earnings history spans 9 years, with the latest figure at -$5.4 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 81.64% year-over-year to -$5.4 million; the TTM value through Dec 2025 reached -$5.4 million, up 81.64%, while the annual FY2025 figure was -$5.4 million, 81.64% up from the prior year.
  • Retained Earnings reached -$5.4 million in Q4 2025 per AUTL's latest filing, up from -$1.3 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$5.4 million in Q4 2025 to a low of -$1.3 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$406.2 million, with a median of -$33.5 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: crashed 4330.51% in 2023, then skyrocketed 98.06% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$8.6 million in 2021, then plummeted by 353.89% to -$38.9 million in 2022, then grew by 25.47% to -$29.0 million in 2023, then decreased by 0.63% to -$29.2 million in 2024, then soared by 81.64% to -$5.4 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Retained Earnings are -$5.4 million (Q4 2025), -$1.3 billion (Q3 2025), and -$1.2 billion (Q2 2025).